Veyonda is a first-in-class activator of the innate immune system. This is the system that scientists increasingly are beginning to see must be activated if a cancer is to have any chance of being permanently eradicated.
Establishing Veyonda as an essential adjunct to radiotherapy in the treatment of prostate cancer and discharging portfolio risk by studying Veyonda in combination with radiotherapy and non-radio therapy treatments.
The Prospectus on this website (Offer Document) relates to the offer of Chess Depositary Interests (CDIs) by Nyrada Inc. ARBN 625 401 818 (Nyrada) and has been prepared to comply with the requirements of the securities laws of Australia. An electronic version of the Offer Document is accessible from this website. Before you attempt to access the electronic version of the Offer Document on this website, you must read this notice in its entirety and indicate your agreement at the bottom of this notice to the terms of access contained on this webpage. If you agree to the terms and conditions contained on this page, you will be given access to the electronic version of the Offer Document.
If you access the electronic version of the Offer Document, you should ensure that you download and consider the Offer Document in full.
Access to the electronic version of the Offer Document is for use only by:
residents of Australia from within Australia;
"professional investors" (as defined in the Securities and Futures Ordinance (Cap. 571) of the Laws of Hong Kong) from within Hong Kong;
"institutional investors" or "relevant persons" (as defined under the Securities and Futures Act, Chapter 289 of Singapore) from within Singapore; or
"qualified investors" (as defined under section 86(7) of the Financial Services and Markets Act 2000) from within the United Kingdom.
It must not be released or distributed in the United States or in any jurisdiction outside of Australia where distribution may be restricted by law.
The Offer Document on this website does not constitute an offer of CDIs in the United States or to any person to whom it would not be lawful outside Australia. The CDIs referred to herein have not been, and will not be, registered under the U.S. Securities Act or under the securities laws of any state or other jurisdiction of the United States. Any CDIs described in, or sold pursuant to, the Offer Document may not be offered or sold in the United States absent registration under the Securities Act or pursuant to an applicable exemption from registration, or to any person to whom it would not be lawful outside Australia.
The CDIs being offered pursuant to the Offer Document are being made available to investors in reliance on the exemption from registration contained in Regulation S of the U.S. Securities Act for offers which are made outside of the U.S. As a result of relying on the Regulation S exemption, the CDIs being offered pursuant to the Offer Document are subject to the restrictions under Regulation S.
Investors must seek advice
Nothing contained on this website or in the Offer Document constitutes investment, legal, business, tax or other advice. In particular, the information on this website and in the Offer Document does not take into account your individual investment objectives, financial or taxation situation or particular needs. In making an investment decision, you must rely on your own examination of Nyrada, the CDIs and the terms of the offer, including the merits and risks involved. You should consult with your accountant, financial adviser, stockbroker, lawyer, tax adviser or other independent and qualified professional adviser if you have any questions in relation to the offer.
The paper form of the electronic version of the Offer Document (including its attached Application Form) accessible through this website has been lodged with the Australian Securities and Investments Commission (ASIC).
Nyrada will apply within 7 days of date of the Offer Document to the Australian Securities Exchange (ASX) for admission to the official list of the ASX and for quotation of the CDIs of Nyrada. Neither ASIC nor ASX takes any responsibility for the contents of the Offer Document or the investment to which it relates.
No offer of CDIs is made on the basis of the electronic version of the Offer Document accessible through this website. An application for CDIs can be made in accordance with the details set out in the Offer Document and the Application Form.
Acceptance of Conditions
By accessing the Offer Document, you represent, warrant and agree that:
you have read, understood and agree to the terms contained in this notice;
a resident of Australia accessing this website from Australia;
a "professional investor" (as defined above) accessing this website from Hong Kong;
a "institutional investor" or "relevant person" (as defined above) accessing this website from Singapore; or
a "qualified investor" (as defined above) accessing this website from the United Kingdom;
you are not a U.S. Person or a person in the United States and you are not acting for the account or benefit of a U.S. Person or a person in the United States; and
you will not release or distribute the Offer Document in the United States or to any U.S. Person or person in the United States or in any other place in which, or to any other person to whom, it is unlawful to do so.
AddressLevel 4, 828 Pacific Highway Gordon. 2072 NSW AUSTRALIA
PO Box 824, Turramurra
2074 NSW AUSTRALIA
50 608 966 123
Join our mailing list to receive the latest information from Noxopharm Limited